Sugi Predict
/ Targets
/ ERBB4
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to ERBB4 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) |
PHASE3 | COMPLETED |
| Overcoming Endocrine Resistance in Metastatic Breast Cancer |
PHASE3 | UNKNOWN |
| Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive |
PHASE3 | COMPLETED |
| Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） |
PHASE2 | RECRUITING |
| Neoadjuvant GW572016 to Treat Breast Cancer |
PHASE2 | COMPLETED |
| Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules |
PHASE2 | UNKNOWN |
| Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer |
PHASE2 | RECRUITING |
| ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy |
PHASE2 | COMPLETED |
| Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer |
PHASE2 | UNKNOWN |
| Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer |
PHASE2 | COMPLETED |
| Afatinib in NSCLC With HER2 Mutation |
PHASE2 | COMPLETED |
| Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance |
PHASE2 | COMPLETED |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) |
PHASE1/PHASE2 | COMPLETED |
| Phase II Study of Vandetanib in Individuals With Kidney Cancer |
PHASE2 | COMPLETED |
| Study of XL647 in Subjects With Non-Small-Cell Lung Cancer |
PHASE2 | COMPLETED |
| Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC |
PHASE2 | COMPLETED |
| First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene |
PHASE2 | UNKNOWN |
| Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer |
PHASE1 | UNKNOWN |
| Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma |
PHASE1 | COMPLETED |
| Assessing the Immunogenicity of pING-hHER3FL |
PHASE1 | ACTIVE_NOT_RECRUITING |
| A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients |
PHASE1 | COMPLETED |
| An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers |
PHASE1 | COMPLETED |
| Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 |
PHASE1 | COMPLETED |
| Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients |
nan | UNKNOWN |
| Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma |
nan | COMPLETED |
| Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Squamous Cell Head and Neck Cancer (HNSCC) to Study Resistance Mechanisms Induced by Standard Therapy |
nan | NOT_YET_RECRUITING |
| Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer |
nan | RECRUITING |
| Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis |
nan | UNKNOWN |
| K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications |
nan | COMPLETED |
| Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a ERBB4 binder may also engage these)